ClinicalTrials.gg
Active, not recruitingNCT05164094Updated May 6, 2026

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

A Phase 1/2 interventional study of mRNA-1189 and Placebo in Epstein-Barr Virus Infection, sponsored by ModernaTX, Inc.. Active, not recruiting at 65 sites in United States. Open to participants aged 10 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
867
Allocation
Randomized
Ages
10 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 76 studies in Epstein-Barr Virus Infections with a site in United States — 19 open to participants now, 25 under way, 2 of them phase 3. Epstein-Barr Virus Infections · United States.

Enrollment
4th of 63
867 · median 25
Started
2021
with 4 others
Phase 1/2
19 of 76
4 open now
Primary completion
2026-10
later than 2 of 23 live
Registered
61st of 76
by date
Lead sponsor
2 of 76
ModernaTX, Inc.

Among the 76 studies in Epstein-Barr Virus Infections with a site in United States, this one is the 4th largest by enrollment of the 63 interventional ones that give a count, is one of 5 that started in 2021, is one of 19 in phase 1/2, reaches primary completion later than 2 of the 23 other live ones, and was the 61st registered.

Epstein-Barr Virus Infections

175 studies on the registry are indexed under Epstein-Barr Virus Infections; 60 are open to participants now.

Browse Epstein-Barr Virus Infections studies →

Open to participants now

19 of the 76 studies in Epstein-Barr Virus Infections with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Epstein-Barr Virus Infections studies recruiting now, 23 (53%) set no upper age limit and 16 (37%) stop at 75 or younger; 23 take children under 18; 6 take healthy volunteers.

This study: 10 Years to 30 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Epstein-Barr Virus Infections with a site in United States, or all of them as a file.
02

Study summary

The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adolescents, and the main objective of Part C is to evaluate the safety and reactogenicity of mRNA-1189 in 10- to 21-year-old healthy adolescents and adults.

03

Conditions studied

  • Epstein-Barr Virus Infection

Keywords

  • Infectious mononucleosis
  • Mononucleosis
04

Who can participate

Ages eligible
10 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • According to the assessment of the investigator, is in good general health and can comply with study procedures.

Part A: Healthy adult from 18 to 30 years of age (inclusive) at the time of consent (Screening Visit, Day 0).

Part B:

Healthy baseline EBV-seronegative adolescents from 12 to \<18 years of age at the time of consent (Screening Visit, Day 0).

Part C:

Healthy adolescents and adults from 10 to 21 years of age (inclusive) at the time of consent (Screening Visit, Day 0).

Exclusion criteria

Exclusion Criteria:

  • Has had significant exposure to someone with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or COVID-19 in the past 14 days prior to the screening visit, if the participant has not been fully vaccinated against COVID-19 at least 14 days prior to the screening visit.
  • Has symptomatic acute or chronic illness requiring ongoing medical or surgical care, to include changes in medication in the past 2 months indicating that chronic illness/disease is not stable (at the discretion of the investigator).
  • Significant, progressive, unstable or uncontrolled clinical condition, including any condition that may affect participant safety, assessment of study endpoints, assessment of immune response, or adherence to study procedures per investigator judgement.
  • Has a history of myocarditis, and/or pericarditis.
  • Has received or plans to receive any licensed or authorized vaccine, to include COVID-19 vaccines, ≤28 days prior to the first injection (Day 1) or plans to receive a licensed vaccine within 28 days before or after any study vaccine injection, with the exception of licensed influenza vaccines, which may be received more than 14 days before or after any study vaccine injection.

Note: Other inclusion and exclusion criteria may apply.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
867 participants (actual)

Study arms

  • Experimental
    Part A: mRNA-1189 Dose Level 2

    Participants will receive 3 intramuscular (IM) injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169.

    Biological: mRNA-1189

  • Experimental
    Part A: mRNA-1189 Dose Level 3

    Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169.

    Biological: mRNA-1189

  • Experimental
    Part A: mRNA-1189 Dose Level 4

    Participants will receive 3 IM injections of mRNA-1189 at Dose Level 4 on Days 1, 57, and 169.

    Biological: mRNA-1189

  • Placebo comparator
    Part A: Placebo

    Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169.

    Biological: Placebo

  • Experimental
    Part B: mRNA-1189 Dose Level 1

    Participants will receive 3 IM injections of mRNA-1189 at Dose Level 1 on Days 1, 57, and 169.

    Biological: mRNA-1189

  • Experimental
    Part B: mRNA-1189 Dose Level 2

    Participants will receive 3 IM injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169.

    Biological: mRNA-1189

  • Experimental
    Part B: mRNA-1189 Dose Level 3

    Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169.

    Biological: mRNA-1189

  • Experimental
    Part B: mRNA-1189 Dose Level 4

    Participants will receive 3 IM injections of mRNA-1189 at Dose Level 4 on Days 1, 57, and 169.

    Biological: mRNA-1189

  • Placebo comparator
    Part B: Placebo

    Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169.

    Biological: Placebo

  • Experimental
    Part C: mRNA-1189 Dose Level 1

    Participants will receive 3 IM injections of mRNA-1189 at Dose Level 1 on Days 1, 57, and 169.

    Biological: mRNA-1189

  • Experimental
    Part C: mRNA-1189 Dose Level 2

    Participants will receive 3 IM injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169.

    Biological: mRNA-1189

  • Experimental
    Part C: mRNA-1189 Dose Level 3

    Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169.

    Biological: mRNA-1189

  • Placebo comparator
    Part C: Placebo

    Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169.

    Biological: Placebo

Interventions

  • BiologicalmRNA-1189

    Sterile liquid for injection

  • BiologicalPlacebo

    0.9% sodium chloride (normal saline) injection

06

What researchers measure

Primary outcomes

  1. Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)

    Time frame: Up to Day 176 (7-day follow-up after vaccination)

  2. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Up to Day 197 (28-day follow-up after vaccination)

  3. Number of Participants with SAEs, MAAEs, Any AEs Leading to Withdrawal From Study/Discontinuation of Study Vaccine and AEs of Special Interest (AESIs)

    Time frame: Day 1 to end of study (EOS) (Day 505)

  4. Number of Participants with Laboratory Abnormalities

    Time frame: Up to Day 176 (7-day follow-up after vaccination)

Secondary outcomes

  1. Geometric Mean Titer (GMT) of B-Cell Neutralizing Antibody (nAb)

    Time frame: Days 1, 85, and 197

  2. Geometric Mean Concentration (GMC) of Antigen-specific Binding Antibody (bAb)

    Time frame: Days 1, 85, and 197

  3. Geometric Mean Fold Rise (GMFR) of B-Cell nAb and Antigen-specific bAb

    Time frame: Days 1, 85, and 197

  4. Number of Participants with Seroresponse of B-Cell nAbs and Antigen-specific bAbs

    The number of participants with seroresponse for EBV-specific (vaccine antigen) binding and nAbs responses and with \>2-, 3-, and 4-fold increases in serum binding or nAb titers from baseline will be analyzed with 2-sided 95% CI using the Clopper-Pearson method by treatment arm and baseline EBV serostatus, and timepoint.

    Time frame: Days 1, 85, and 197

07

Study locations

65 sites
08

References and documents

Publications

  • Malpica L, Marques-Piubelli ML, Beltran BE, Chavez JC, Miranda RN, Castillo JJ. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk-stratification, and management. Am J Hematol. 2024 Oct;99(10):2002-2015. doi: 10.1002/ajh.27430. Epub 2024 Jul 3. PubMed 38957951 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2021 (actual). Primary completion is estimated for Oct 2026, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2021
First posted
Dec 20, 2021
StartActual
Dec 28, 2021
Primary completionEst.
Oct 5, 2026
CompletionEst.
Aug 18, 2027
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05164094
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Dec 20, 2021
Start date
Dec 28, 2021
Primary completion
Oct 5, 2026 (estimated)
Completion
Aug 18, 2027 (estimated)
Last update
May 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion